 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Is Aspirin a Cost-Effective Addition to Colorectal Cancer Screening?
6 November 2001 | Volume 135 Issue 9 | Page S51
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Aspirin as an Adjunct to Screening for Prevention of Sporadic Colorectal Cancer. A Cost-Effectiveness Analysis." It is in the 6 November 2001 issue of Annals of Internal Medicine (volume 135, pages 769-781). The authors are U Ladabaum, CL Chopra, G Huang, JM Scheiman, ME Chernew, and AM Fendrick.
What is the problem and what is known about it so far?
Colorectal cancer is cancer of the colon (large intestine) or rectum. Screening decreases deaths from colorectal cancer by detecting precancerous abnormalities (polyps) and removing them before they become cancer and by detecting cancer in an early stage when it can still be cured with surgery. Screening tests include fecal occult blood testing (FOBT), flexible sigmoidoscopy, and colonoscopy. FOBT uses a chemical reaction to detect blood hidden in stool. Polyps and colorectal cancers can cause blood to leak into the stool, so a positive result on FOBT suggests the need for further testing. Flexible sigmoidoscopy involves looking into the rectum and lower colon through a tube-shaped instrument; colonoscopy uses a similar but longer instrument to look at the entire length of the colon. While it is not clear which screening strategy makes the most sense in terms of costs and associated benefits, it is clear that some form of routine screening is favorable after age 50 in terms of health benefits and economics. Taking an aspirin a day may also help to prevent colorectal cancer. However, the degree of benefit from aspirin is unclear, and aspirin can cause bleeding complications.
Why did the researchers do this particular study?
To find out whether adding daily aspirin to regular colorectal cancer screening makes sense in terms of health benefits and costs.
Who was studied?
Rather than studying actual patients, the researchers used computers to simulate what would happen to a "virtual" group of patients 50 to 80 years of age. They assumed that patients had no special risks for colon cancer.
How was the study done?
The researchers used published information to estimate what might happen (and how much it would cost) if patients took aspirin in addition to having regular screening for colorectal cancer. They put these estimates into a computer model and calculated how much adding aspirin would cost for each year of life it saves.
What did the researchers find?
The researchers found that using aspirin to prevent colorectal cancer in regularly screened patients costs more per year of life it saves than society typically finds acceptable. This is due in large part to the complications caused by aspirin.
What were the limitations of the study?
This study was a computer simulation, so we cannot be sure what the results would be with actual patients.
What are the implications of the study?
Aspirin alone cannot be considered a substitute for colorectal cancer screening. In terms of costs and benefits, it does not make sense to prescribe aspirin primarily to prevent colorectal cancer in patients who get regular screening.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  R. S. Sandler Aspirin Should Not Be Promoted for Colon Cancer Prevention: Counterpoint Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1562 - 1563. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Tappenden, J. Chilcott, S. Eggington, H. Sakai, J. Karnon, and J. Patnick Option appraisal of population-based colorectal cancer screening programmes in England Gut, May 1, 2007; 56(5): 677 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Martinez and E. R. Greenberg More Aspirin for Less Cancer? J Natl Cancer Inst, April 18, 2007; 99(8): 582 - 583. [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Roy, D. P. Kunte, J. L. Koetsier, J. Hart, Y. L. Kim, Y. Liu, M. Bissonnette, M. Goldberg, V. Backman, and R. K. Wali Chemoprevention of colon carcinogenesis by polyethylene glycol: suppression of epithelial proliferation via modulation of SNAIL/{beta}-catenin signaling. Mol. Cancer Ther., August 1, 2006; 5(8): 2060 - 2069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pignone, S. Earnshaw, J. A. Tice, and M. J. Pletcher Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med, March 7, 2006; 144(5): 326 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-H. Chang, T. H.-H. Chen, H.-M. Hsu, T.-C. Wu, M.-S. Kong, D.-C. Liang, Y.-H. Ni, C.-J. Chen, D.-S. Chen, and for the Taiwan Childhood HCC Study Group Prevention of Hepatocellular Carcinoma by Universal Vaccination against Hepatitis B Virus: The Effect and Problems Clin. Cancer Res., November 1, 2005; 11(21): 7953 - 7957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yao, W. Zhou, S. Sangha, A. Albert, A. J. Chang, T. C. Liu, and M. M. Wolfe Effects of Nonselective Cyclooxygenase Inhibition with Low-Dose Ibuprofen on Tumor Growth, Angiogenesis, Metastasis, and Survival in a Mouse Model of Colorectal Cancer Clin. Cancer Res., February 15, 2005; 11(4): 1618 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Chan, E. L. Giovannucci, E. S. Schernhammer, G. A. Colditz, D. J. Hunter, W. C. Willett, and C. S. Fuchs A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma Ann Intern Med, February 3, 2004; 140(3): 157 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Sandler Aspirin Prevention of Colorectal Cancer: More or Less? Ann Intern Med, February 3, 2004; 140(3): 224 - 225. [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Sandler, S. Halabi, J. A. Baron, S. Budinger, E. Paskett, R. Keresztes, N. Petrelli, J. M. Pipas, D. D. Karp, C. L. Loprinzi, et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer N. Engl. J. Med., March 6, 2003; 348(10): 883 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Baron, B. F. Cole, R. S. Sandler, R. W. Haile, D. Ahnen, R. Bresalier, G. McKeown-Eyssen, R. W. Summers, R. Rothstein, C. A. Burke, et al. A Randomized Trial of Aspirin to Prevent Colorectal Adenomas N. Engl. J. Med., March 6, 2003; 348(10): 891 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yao, S. Kargman, E. C. Lam, C. R. Kelly, Y. Zheng, P. Luk, E. Kwong, J. F. Evans, and M. M. Wolfe Inhibition of Cyclooxygenase-2 by Rofecoxib Attenuates the Growth and Metastatic Potential of Colorectal Carcinoma in Mice Cancer Res., February 1, 2003; 63(3): 586 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Using Aspirin to Prevent Colon Cancer: A Cost Analysis Journal Watch Gastroenterology, November 27, 2001; 2001(1127): 1 - 1. [Full Text]
|
|
|
|
 |
|
 Aspirin Prophylaxis for Colon Cancer: Not Good Enough Journal Watch (General), November 13, 2001; 2001(1113): 1 - 1. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
